MD Anderson, Exscientia collaborate to develop oncology treatments using AI

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

In Brief

MD Anderson, Rice form Cancer Bioengineering Collaborative

The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Upregulating TERT gene expression reverses multiple hallmarks of aging

Researchers at MD Anderson Cancer Center have demonstrated that therapeutically restoring ‘youthful’ levels of a specific subunit of the telomerase enzyme can significantly reduce the signs and symptoms of aging in preclinical models.

June 28, 2024

Vol.50 No.26

Drugs & Targets

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round.

June 28, 2024

Vol.50 No.26

In Brief

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

The Institute for Data Science in Oncology at MD Anderson Cancer Center has established an internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.

June 21, 2024

Vol.50 No.25

MD Anderson, Exscientia collaborate to develop oncology treatments using AI

YOU MAY BE INTERESTED IN

Exscientia builds AWS AI-powered platform to advance drug discovery

MD Anderson, Rice form Cancer Bioengineering Collaborative

Upregulating TERT gene expression reverses multiple hallmarks of aging

Merck, Qure.ai collaborate to expand lung cancer detection via AI

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Renew today!

Subscriber content

Login